Over the past year the excitement in biopharma R&D circles about the therapeutic punch of cancer immunotherapies has reached fever pitch, and the intense R&D focus hasn't escaped the notice of top analysts who are making some megablockbuster projections on the commercial impact these new drugs are likely to have. Report